S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
NASDAQ:VTVT

vTv Therapeutics News Headlines

$0.45
-0.02 (-4.48%)
(As of 05/20/2022 04:00 PM ET)
Add
Compare
Today's Range
$0.42
$0.54
50-Day Range
$0.39
$0.84
52-Week Range
$0.38
$2.88
Volume
202,600 shs
Average Volume
256,180 shs
Market Capitalization
$40.85 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
-1.43
Get vTv Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for VTVT and its competitors with MarketBeat's FREE daily newsletter.

Media Mentions By Week

vTv Therapeutics Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

VTVT
News Sentiment

0.00

0.30

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

VTVT Articles
This Week

4

1

VTVT Articles
Average Week



vTv Therapeutics (NASDAQ:VTVT) News Headlines Today

SourceHeadline
MarketBeat logoComparing vTv Therapeutics (NASDAQ:VTVT) and 89bio (NASDAQ:ETNB)
americanbankingnews.com - May 21 at 2:02 AM
MarketBeat logovTv Therapeutics (NASDAQ:VTVT) Stock Rating Upgraded by Zacks Investment Research
americanbankingnews.com - May 20 at 4:02 AM
MarketBeat logoZacks Investment Research Upgrades vTv Therapeutics (NASDAQ:VTVT) to Buy
americanbankingnews.com - May 16 at 3:02 AM
seekingalpha.com logovTv Therapeutics GAAP EPS of -$0.10, revenue of $2M
seekingalpha.com - May 14 at 6:43 PM
MarketBeat logovTv Therapeutics (NASDAQ:VTVT) Coverage Initiated by Analysts at StockNews.com
americanbankingnews.com - May 13 at 1:24 AM
finance.yahoo.com logovTv Therapeutics Announces 2022 First Quarter Financial Results and Provides Corporate Update
finance.yahoo.com - May 12 at 11:33 AM
MarketBeat logovTv Therapeutics (NASDAQ:VTVT) Rating Lowered to Hold at Zacks Investment Research
americanbankingnews.com - May 12 at 3:20 AM
MarketBeat logovTv Therapeutics (NASDAQ:VTVT) Share Price Crosses Below 50 Day Moving Average of $0.69
americanbankingnews.com - May 5 at 4:52 AM
MarketBeat logo Brokerages Anticipate vTv Therapeutics Inc. (NASDAQ:VTVT) Will Announce Earnings of -$0.08 Per Share
americanbankingnews.com - May 5 at 2:14 AM
bizjournals.com logovTv Therapeutics reports $17.6M loss in 2021, names new acting CEO
bizjournals.com - April 1 at 9:04 AM
finance.yahoo.com logovTv Therapeutics (NASDAQ:VTVT) investors are sitting on a loss of 89% if they invested five years ago
finance.yahoo.com - March 31 at 11:03 PM
benzinga.com logovTv Therapeutics's Return On Capital Employed Overview
benzinga.com - March 31 at 6:02 PM
finance.yahoo.com logovTv Therapeutics Announces 2021 fourth Quarter and Full Year Financial Results and Provides Corporate Update
finance.yahoo.com - March 29 at 10:41 PM
markets.businessinsider.com logoThe Daily Biotech Pulse: Ocugen Faces Regulatory Setback, vTv CEO Quits, Biogen-Eisai Make Headway With Second Alzheimer's Antibody Treatment In Japan
markets.businessinsider.com - March 4 at 2:46 PM
benzinga.com logoVTv Therapeutics Says On Feb. 27 Deepra Prasad Notified Board Of Decision To Resign As CEO
benzinga.com - March 4 at 3:02 AM
finance.yahoo.com logovTv Therapeutics Announces CEO Transition
finance.yahoo.com - March 3 at 10:00 PM
benzinga.com logoCantor Fitzgerald Initiates Coverage On vTv Therapeutics with Overweight Rating, Announces Price Target of $5
benzinga.com - February 18 at 9:43 AM
finance.yahoo.com logovTv Therapeutics Shares Updated Corporate Presentation
finance.yahoo.com - January 13 at 10:45 AM
nasdaq.com logovTv Therapeutics Inc - Class A Shares Approach 52-Week Low - Market Mover
nasdaq.com - December 21 at 7:54 AM
bizjournals.com logoTriad pharmaceutical company lays off 65% of its workforce two months after leadership change
bizjournals.com - December 7 at 6:08 PM
finance.yahoo.com logoVTv Therapeutics slashes 65% of workforce, focuses on its diabetes drug
finance.yahoo.com - December 7 at 2:26 AM
finance.yahoo.com logovTv Therapeutics Announces Restructuring to Prioritize its Lead Program and Focus Operations
finance.yahoo.com - December 6 at 9:26 PM
finance.yahoo.com logoHere's Why vTv Therapeutics (VTVT) is Poised for a Turnaround After Losing 15.2% in 4 Weeks
finance.yahoo.com - December 3 at 1:35 PM
finance.yahoo.com logoTriad pharmaceutical company ranks high in Deloitte’s 2021 Technology Fast 500 list
finance.yahoo.com - November 22 at 7:35 AM
finance.yahoo.com logoVTv Therapeutics (VTVT) Reports Q3 Loss, Tops Revenue Estimates
finance.yahoo.com - November 9 at 2:40 PM
finance.yahoo.com logovTv Therapeutics Announces 2021 Third Quarter Financial Results and Provides Corporate Update
finance.yahoo.com - November 9 at 9:39 AM
finance.yahoo.com logoEarnings Preview: vTv Therapeutics (VTVT) Q3 Earnings Expected to Decline
finance.yahoo.com - October 28 at 8:08 PM
finance.yahoo.com logoHere's Why We're Watching vTv Therapeutics' (NASDAQ:VTVT) Cash Burn Situation
finance.yahoo.com - October 28 at 3:08 PM
nasdaq.com logoVTv Names Deepa Prasad New CEO
nasdaq.com - October 20 at 10:07 AM
nasdaq.com logoVTv: Study Result Shows TTP399 Lowers Blood Glucose Without Increasing Risk Of Diabetic Ketoacidosis
nasdaq.com - October 12 at 12:11 PM
finance.yahoo.com logovTv Therapeutics Announces Positive Results from Mechanistic Study Indicating No Increased Risk of Ketoacidosis with TTP399 during Acute Insulin Withdrawal in Patients with Type 1 Diabetes
finance.yahoo.com - October 12 at 12:11 PM
benzinga.com logoUPDATE: vTv Therapeutics Says 'HPP737 exhibited favorable safety and tolerability profile, with no dose limiting gastrointestinal side effects'
benzinga.com - September 23 at 7:47 PM
finance.yahoo.com logovTv Therapeutics Announces Results of Multiple Ascending Dose Study and Development Plan for HPP737, an Oral PDE4 Inhibitor for the Treatment of Psoriasis
finance.yahoo.com - September 23 at 7:47 PM
nasdaq.com logoIs vTv Therapeutics (NASDAQ:VTVT) In A Good Position To Invest In Growth?
nasdaq.com - September 14 at 4:08 PM
finance.yahoo.com logoMultiple insiders bought vTv Therapeutics Inc. (NASDAQ:VTVT) stock earlier this year, a positive sign for shareholders
finance.yahoo.com - September 13 at 5:56 PM
finance.yahoo.com logoDown 16.1% in 4 Weeks, Here's Why vTv Therapeutics (VTVT) Looks Ripe for a Turnaround
finance.yahoo.com - August 17 at 12:20 PM
finance.yahoo.com logoVTv Therapeutics (VTVT) Reports Q2 Loss, Lags Revenue Estimates
finance.yahoo.com - August 4 at 11:20 PM
finance.yahoo.com logovTv Therapeutics Announces 2021 Second Quarter Financial Results and Provides Corporate Update
finance.yahoo.com - August 4 at 6:20 PM
nasdaq.com logoA Look At vTv Therapeutics' (NASDAQ:VTVT) Share Price Returns
nasdaq.com - July 28 at 11:23 PM
finance.yahoo.com logovTv Therapeutics (NASDAQ:VTVT) Share Prices Have Dropped 66% In The Last Five Years
finance.yahoo.com - July 27 at 2:40 PM
finance.yahoo.com logovTv Therapeutics to Participate at the 6th World Psoriasis & Psoriatic Arthritis Conference with Poster Presentation on HPP737
finance.yahoo.com - June 29 at 7:52 AM
finance.yahoo.com logovTv Therapeutics Shares Jump On Out-Licensing Agreement For Azeliragon In Cancer Settings
finance.yahoo.com - June 22 at 5:59 PM
msn.com logoWhy Moderna, Bio-Path Holdings And vTv Therapeutics Are Moving Today
msn.com - June 22 at 12:58 PM
finance.yahoo.com logovTv Therapeutics and Cantex Pharmaceuticals Announce Strategic Licensing Agreement for Development and Commercialization of Azeliragon for Treatment of Cancer
finance.yahoo.com - June 22 at 7:58 AM
nasdaq.com logovTv Therapeutics Inc. (NASDAQ:VTVT) Insiders Increased Their Holdings
nasdaq.com - May 25 at 6:33 PM
finance.yahoo.com logoWhat Kind Of Shareholders Own vTv Therapeutics Inc. (NASDAQ:VTVT)?
finance.yahoo.com - May 25 at 1:33 PM
finance.yahoo.com logoVTv Therapeutics (VTVT) Reports Q1 Loss, Tops Revenue Estimates
finance.yahoo.com - May 5 at 9:52 PM
finance.yahoo.com logovTv Therapeutics Announces 2021 First Quarter Financial Results and Provides Corporate Update
finance.yahoo.com - May 5 at 4:48 PM
ca.finance.yahoo.com logovTv Therapeutics Stock Is Believed To Be Significantly Overvalued
ca.finance.yahoo.com - April 15 at 11:00 PM
finance.yahoo.com logovTv Therapeutics (VTVT) Gets Breakthrough Tag for Diabetes Drug
finance.yahoo.com - April 14 at 1:09 PM
Get vTv Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for VTVT and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 5/23/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.